CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 11 enrolled
Drug / intervention
Extracoporeal shock wave therapy +1 moredevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04161183
NCT04161183N/ACompleted

Extracoporeal Shock Wave Therapy (ESWT) for the Treatment of Detrusor Underactivity/ Underactive Bladder (DU/UAB) - a Single Center, Randomized, Double-blind, Placebo-controlled, Prospective Study

Chang Gung Memorial Hospital·interventional·Posted Nov 13, 2019·Updated Oct 5, 2022

In Brief

A clinical study evaluating Extracoporeal shock wave therapy and Placebo for Detrusor, Underactive and Detrusor Underactivity. Completed, enrolled 11 participants across 1 site.

Detailed Summary

To evaluate the efficacy and safety of ESWT for the treatment of patients with DU/UAB

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesTaiwan
Collaborators--

Timeline

N/ACompletedFinished
2020202120222023202420252026
First PostedNov 13, 2019
Enrollment StartOct 15, 2019
Primary CompletionDec 1, 2021
Study CompletionAug 10, 2022
TodayJul 2, 2026
Enrollment to primary: 2.1 yearsPosted 6.6 years ago

Interventions

Extracoporeal shock wave therapydevice

Probe be transcutaneous applied to the region of bladder dome, right upper lateral wall, right lower lateral wall, left upper lateral wall, and left lower lateral wall with 2500 shocks, frequency of 4 pulses per second and maximum total energy flow density 0.25 millijoule/mm2 once a week for 6 weeks

Placebodevice

Probe be transcutaneous applied to the region of bladder dome, right upper lateral wall, right lower lateral wall, left upper lateral wall, and left lower lateral wall with 2500 shocks, frequency of 4 pulses per second but no energy once a week for 6 weeks